

1

2

3 **INVITRO BIOCHEMICAL STUDIES ON ORGANOMETALLIC**
4 **COMPOUNDS AS ANTICANCER AGENTS**

ABSTRACT:

5

This study aims to synthesis of copper complexes of 2,3-dihydroxy benzaldehyde thiosemicarbazone (3a,b), followed by evaluating their in vitro anticancer properties. The prepared compounds have been also evaluated for their ability to induce apoptosis. A total number of 80 adult female swiss albino mice weighing 20-25 gm were divided randomly into 8 groups (10 mice /each group). The *in vitro* cytotoxic activities of compounds (3a, 3b) were evaluated. Minimum inhibitory concentrations of synthesized compound 3a were found to be 50 µg/mL against MCF-7, HepG2 and PC3 cell lines; also, Minimum inhibitory concentrations of synthesized compound 3b were found to be 50 µg/mL in all cell lines. The apoptotic effect of compounds 3a and 3b were evaluated by measurement Caspase-3 activity and Bcl-2 concentration. The mean values of Caspase-3 activity in positive control were found to be 2.6151 (ng/mL). On the other hand, the mean values of Bcl-2 in positive control were found to be 3.7 (ng/mL). The compounds (3a & 3b) exhibited a significant anticancer activity towards MCF-7, HEPG2 and PC3 cancer cell lines.

Keywords:

18

in vitro anticancer properties,copper complexes, 2,3-dihydroxy benzaldehyde thiosemicarbazone, adult female swiss albino mice, MCF-7, HepG2 and PC3 cell lines.

1. INTRODUCTION:

22

Cancer is one of the leading causes of death in the developed world. Tumor is a group of cells that have undergone un- regulated growth, and will often form a mass or lump, but may be distributed diffusely [1].Carcinogenesis, also called oncogenesis or tumorigenesis, is the formation of a cancer, where normal cells are transformed into cancer cells. The process is characterized by changes at cellular, genetic, and epigenetic levels and abnormal cell division. Cell division is a physiological process that occurs in almost all tissues and under a variety of circumstances. Normally the balance between proliferation and programmed cell death, in the form of apoptosis, is maintained to ensure the integrity of tissues and organs [2].

Cancer is a disease characterized by failure of tissue growth regulation when the genes that regulate cell growth and differentiation are altered. Most cancers have multiple causes, only a small minority of cancer are due to inherited genetic mutations whereas the vast majority are non-hereditary epigenetic mutations that are caused by various agents (environmental factors, physical factors and hormones). Thus, although there are some genetic predispositions in a small fraction of cancers, the major fraction is due to a set of new genetic mutations (called “epigenetic” mutations) [3].

The quest for alternative drugs to the well-known cisplatin and its derivatives, which are still used in more than 50% of the treatment regimes for patients suffering from cancer, is highly needed. Despite their tremendous success, these platinum compounds suffer from two main disadvantages: they are inefficient against platinum-resistant tumors, and they have severe side effects such as nephrotoxicity. The latter drawback is the consequence of the fact that the ultimate target of these drugs is ubiquitous. In this context, organometallic compounds, which are defined as metal complexes containing at least one direct, covalent metal-carbon bond, have recently been found to be promising anticancer drug candidates [4].

Current emphasis towards the development organometallic chemotherapeutics has attracted many researchers in the search for new cancer therapeutic agents with improved activity and less toxicity. For centuries, organometallic compounds have been reviewed as catalysts, but are now studied in the exploration of new potential anticancer drugs after the landmark investigation on titanocene by Kopf and Kopf-Maier. Subsequently, several titanocene-based organometallic complexes entered clinical trials and their mechanism of action was found to be different to that of the clinically approved drug cisplatin [5].

This study aims to the synthesis of copper complexes of 2,3-dihydroxy benzaldehyde thiosemicarbazone (3a,b), followed by evaluation of their in vitro anticancer properties and their ability to induce apoptosis.


2. MATERIALS & METHODS:

2.1 Materials:

- Chemicals for synthesis of copper complexes of 2,3-dihydroxy-benzaldehyde thiosemicarbazones (3a,b) : 2,3-dihydroxybenzaldehyde; 5,6-dibromo-2,3-dihydroxybenzaldehyde; Thiosemicarbazide; Copper chloride; Ammonium hydroxide (10%) and ethanol.
- Sigma Aldrich Chemical Co., St. Louis, Mo, U.S.A., was the source of the following chemicals: RPMI-1640 medium, Trypan blue, Fetal Bovine Serum, Penicillin/ Streptomycin antibiotic and trypsin- EDTA.
- RPMI-1640 medium, Trypan blue dye, Fetal Bovine Serum (FBS), Penicillin/ Streptomycin, trypsin- EDTA.
- Human tumor cell lines MCF-7 (human breast cancer), HePG2 (Hepatocellular carcinoma), and PC3 (human prostate cancer) cell lines were used in this study obtained from the American Type Culture Collection (ATCC, Minisota, U.S.A.). The tumor cell lines were maintained at the National Cancer Institute, Cairo, Egypt, by serial sub-culturing.

2.2 Methods:

- Synthesis of 2,3-dihydroxybenzaldehyde thiosemicarbazones derivatives (2a, b) were obtained from the condensation of aromatic aldehydes (namely , 2,3-dihydroxybenzaldehyde & 5,6-dibromo-2,3-dihydroxybenzaldehyde) with thiosamicarbazide in ethanol under reflux. The copper complexes of 2,3-dihydroxybenzaldehyde thiosemicarbazones derivatives (3a, b) were prepared from the reaction of thiosemicarbazone derivatives (2a,b) with two mole of copper chloride in ethanol under reflux (scheme 1).



79

80 **Scheme 1:** synthesis of the compounds (2a, 2b, 3a & 3b).

81

82 - **Groups of the study:**

A total number of 80 adult female swiss albino mice weighing 20-25 gm were divided randomly into 8 groups (10 mice /each group) as following:

Group (1): Negative Control: This group received sterile saline solution (0.9 % NaCl) day after day for 9 days.

Group (2): Positive Control: This group received Ehrlich ascites carcinoma (EAC), (2.5×10^6 cells/ 0.3 ml/mouse) by (I.P) injection once at the first day.

Group (3): Drug group I: This group consisted of 10 mice were injected I.P. with compound 3a (5 mg/Kg) at 1, 3, 5, 7, 9 days for 10 days (day after day).

Group (4): Preventive group I: (EAC + compound 3a): This group were injected I.P. with compound 3a (5 mg/Kg) in the day before EAC injection (2.5×10^6 cells/mouse), followed by I.P. injection of compound 3a at 3, 5, 7, 9 days of EAC injection for 10 days (day after day).

Group (5): Therapeutic group I: (EAC + compound 3a): This group were injected I.P. with compound 3a (5 mg/Kg) in the day after EAC injection (2.5×10^6 cells/mouse), followed by I.P. injection of compound 3a at 3, 5, 7, 9 days of EAC injection for 10 days (day after day).

Group (6): Drug group II: This group were injected I.P. with compound 3b (10 mg/Kg) at 1, 3, 5, 7, 9 days for 10 days (day after day).

Group (7): Preventive Group II: (EAC + compound 3b): This group were injected I.P. with compound 3b (10 mg/Kg) in the day before EAC injection (2.5×10⁶ cells/mouse), followed by I.P. injection of compound 3b at 3, 5, 7, 9 days of EAC injection for 10 days (day after day).

Group (8): Therapeutic Group II: (EAC + compound 3b): This group were injected I.P. with compound 3b (10 mg/Kg) in the day after EAC injection (2.5×10⁶ cells/mouse), followed by I.P. injection of compound 3b at 3, 5, 7, 9 days of EAC injection for 10 days (day after day).

110

- **111**lood , EAC and tissue sampling:

112the end of the experiment, the blood samples were collected from the retro-orbital venous **113** **114** **115** **116** **117** **118** **119** **120** **121** **122** **123** **124** **125** **126** **127** **128** **129** **130** **131** **132** **133** **134** **135** **136** **137** **138** **139** **140** **141** **142** **143** **144** **145** **146** **147** **148** **149** **150** **151** **152** **153** **154** **155** **156** **157** **158** **159** **160** **161** **162** **163** **164** **165** **166** **167** **168** **169** **170** **171** **172** **173** **174** **175** **176** **177** **178** **179** **180** **181** **182** **183** **184** **185** **186** **187** **188** **189** **190** **191** **192** **193** **194** **195** **196** **197** **198** **199** **200** **201** **202** **203** **204** **205** **206** **207** **208** **209** **210** **211** **212** **213** **214** **215** **216** **217** **218** **219** **220** **221** **222** **223** **224** **225** **226** **227** **228** **229** **230** **231** **232** **233** **234** **235** **236** **237** **238** **239** **240** **241** **242** **243** **244** **245** **246** **247** **248** **249** **250** **251** **252** **253** **254** **255** **256** **257** **258** **259** **260** **261** **262** **263** **264** **265** **266** **267** **268** **269** **270** **271** **272** **273** **274** **275** **276** **277** **278** **279** **280** **281** **282** **283** **284** **285** **286** **287** **288** **289** **290** **291** **292** **293** **294** **295** **296** **297** **298** **299** **300** **301** **302** **303** **304** **305** **306** **307** **308** **309** **310** **311** **312** **313** **314** **315** **316** **317** **318** **319** **320** **321** **322** **323** **324** **325** **326** **327** **328** **329** **330** **331** **332** **333** **334** **335** **336** **337** **338** **339** **340** **341** **342** **343** **344** **345** **346** **347** **348** **349** **350** **351** **352** **353** **354** **355** **356** **357** **358** **359** **360** **361** **362** **363** **364** **365** **366** **367** **368** **369** **370** **371** **372** **373** **374** **375** **376** **377** **378** **379** **380** **381** **382** **383** **384** **385** **386** **387** **388** **389** **390** **391** **392** **393** **394** **395** **396** **397** **398** **399** **400** **401** **402** **403** **404** **405** **406** **407** **408** **409** **410** **411** **412** **413** **414** **415** **416** **417** **418** **419** **420** **421** **422** **423** **424** **425** **426** **427** **428** **429** **430** **431** **432** **433** **434** **435** **436** **437** **438** **439** **440** **441** **442** **443** **444** **445** **446** **447** **448** **449** **450** **451** **452** **453** **454** **455** **456** **457** **458** **459** **460** **461** **462** **463** **464** **465** **466** **467** **468** **469** **470** **471** **472** **473** **474** **475** **476** **477** **478** **479** **480** **481** **482** **483** **484** **485** **486** **487** **488** **489** **490** **491** **492** **493** **494** **495** **496** **497** **498** **499** **500** **501** **502** **503** **504** **505** **506** **507** **508** **509** **510** **511** **512** **513** **514** **515** **516** **517** **518** **519** **520** **521** **522** **523** **524** **525** **526** **527** **528** **529** **530** **531** **532** **533** **534** **535** **536** **537** **538** **539** **540** **541** **542** **543** **544** **545** **546** **547** **548** **549** **550** **551** **552** **553** **554** **555** **556** **557** **558** **559** **560** **561** **562** **563** **564** **565** **566** **567** **568** **569** **570** **571** **572** **573** **574** **575** **576** **577** **578** **579** **580** **581** **582** **583** **584** **585** **586** **587** **588** **589** **590** **591** **592** **593** **594** **595** **596** **597** **598** **599** **600** **601** **602** **603** **604** **605** **606** **607** **608** **609** **610** **611** **612** **613** **614** **615** **616** **617** **618** **619** **620** **621** **622** **623** **624** **625** **626** **627** **628** **629** **630** **631** **632** **633** **634** **635** **636** **637** **638** **639** **640** **641** **642** **643** **644** **645** **646** **647** **648** **649** **650** **651** **652** **653** **654** **655** **656** **657** **658** **659** **660** **661** **662** **663** **664** **665** **666** **667** **668** **669** **670** **671** **672** **673** **674** **675** **676** **677** **678** **679** **680** **681** **682** **683** **684** **685** **686** **687** **688** **689** **690** **691** **692** **693** **694** **695** **696** **697** **698** **699** **700** **701** **702** **703** **704** **705** **706** **707** **708** **709** **710** **711** **712** **713** **714** **715** **716** **717** **718** **719** **720** **721** **722** **723** **724** **725** **726** **727** **728** **729** **730** **731** **732** **733** **734** **735** **736** **737** **738** **739** **740** **741** **742** **743** **744** **745** **746** **747** **748** **749** **750** **751** **752** **753** **754** **755** **756** **757** **758** **759** **760** **761** **762** **763** **764** **765** **766** **767** **768** **769** **770** **771** **772** **773** **774** **775** **776** **777** **778** **779** **780** **781** **782** **783** **784** **785** **786** **787** **788** **789** **790** **791** **792** **793** **794** **795** **796** **797** **798** **799** **800** **801** **802** **803** **804** **805** **806** **807** **808** **809** **810** **811** **812** **813** **814** **815** **816** **817** **818** **819** **820** **821** **822** **823** **824** **825** **826** **827** **828** **829** **830** **831** **832** **833** **834** **835** **836** **837** **838** **839** **840** **841** **842** **843** **844** **845** **846** **847** **848** **849** **850** **851** **852** **853** **854** **855** **856** **857** **858** **859** **860** **861** **862** **863** **864** **865** **866** **867** **868** **869** **870** **871** **872** **873** **874** **875** **876** **877** **878** **879** **880** **881** **882** **883** **884** **885** **886** **887** **888** **889** **890** **891** **892** **893** **894** **895** **896** **897** **898** **899** **900** **901** **902** **903** **904** **905** **906** **907** **908** **909** **910** **911** **912** **913** **914** **915** **916** **917** **918** **919** **920** **921** **922** **923** **924** **925** **926** **927** **928** **929** **930** **931** **932** **933** **934** **935** **936** **937** **938** **939** **940** **941** **942** **943** **944** **945** **946** **947** **948** **949** **950** **951** **952** **953** **954** **955** **956** **957** **958** **959** **960** **961** **962** **963** **964** **965** **966** **967** **968** **969** **970** **971** **972** **973** **974** **975** **976** **977** **978** **979** **980** **981** **982** **983** **984** **985** **986** **987** **988** **989** **990** **991** **992** **993** **994** **995** **996** **997** **998** **999** **1000**

116

- **117**etermination and counting of viable cells: 1-50µL of 0.05 % Trypan blue solution was added to 50µL **118** the single cell suspension. The cells were examined under the inverted microscope using the **119** hemocytometer. Non stained (viable) cells were counted and the following equation was used to **120** calculate the cell count /ml of cell suspension.

$$\text{Viable cells /mL} = \text{number of cells in 4 quarters} \times 2 \text{ (dilution factor)} \times 10^4 \quad 121$$

The cells were then diluted to give the required cell number for each experiment. **122**

Cryopreservation of cells: To avoid the loss of the cell line, excess cells were preserved in liquid **123**


nitrogen as follows: Equal parts of the cell suspension and freezing medium (10 % DMSO In **124**

supplemented medium) were dispersed to cryotubes. The cryotubes were racked in appropriately **125**


labeled polystyrene boxes, gradually cooled till reaching -80 °C. Then the cryotubes were stored in a **126**

liquid nitrogen (-180 °C) till use [7]. **127**

- **128**etermination of potential cytotoxicity of synthetic compounds on human cancer cell **129**: The cytotoxicity was carried out using Sulphorhodamine-B (SRB) assay. SRB is a bright pink **130** **131** **132** **133** **134** **135** **136** **137** **138** **139** **140** **141** **142** **143** **144** **145** **146** **147** **148** **149** **150** **151** **152** **153** **154** **155** **156** **157** **158** **159** **160** **161** **162** **163** **164** **165** **166** **167** **168** **169** **170** **171** **172** **173** **174** **175** **176** **177** **178** **179** **180** **181** **182** **183** **184** **185** **186** **187** **188** **189** **190** **191** **192** **193** **194** **195** **196** **197** **198** **199** **200** **201** **202** **203** **204** **205** **206** **207** **208** **209** **210** **211** **212** **213** **214** **215** **216** **217** **218** **219** **220** **221** **222** **223** **224** **225** **226** **227** **228** **229** **230** **231** **232** **233** **234** **235** **236** **237** **238** **239** **240** **241** **242** **243** **244** **245** **246** **247** **248** **249** **250** **251** **252** **253** **254** **255** **256** **257** **258** **259** **260** **261** **262** **263** **264** **265** **266** **267** **268** **269** **270** **271** **272** **273** **274** **275** **276** **277** **278** **279** **280** **281** **282** **283** **284** **285** **286** **287** **288** **289** **290** **291** **292** **293** **294** **295** **296** **297** **298** **299** **300** **301** **302** **303** **304** **305** **306** **307** **308** **309** **310** **311** **312** **313** **314** **315** **316** **317** **318** **319** **320** **321** **322** **323** **324** **325** **326** **327** **328** **329** **330** **331** **332** **333** **334** **335** **336** **337** **338** **339** **340** **341** **342** **343** **344** **345** **346** **347** **348** **349** **350** **351** **352** **353** **354** **355** **356** **357** **358** **359** **360** **361** **362** **363** **364** **365** **366** **367** **368** **369** **370** **371** **372** **373** **374** **375** **376** **377** **378** **379** **380** **381** **382** **383** **384** **385** **386** **387** **388** **389** **390** **391** **392** **393** **394** **395** **396** **397** **398** **399** **400** **401** **402** **403** **404** **405** **406** **407** **408** **409** **410** **411** **412** **413** **414** **415** **416** **417** **418** **419** **420** **421** **422** **423** **424** **425** **426** **427** **428** **429** **430** **431** **432** **433** **434** **435** **436** **437** **438** **439** **440** **441** **442** **443** **444** **445** **446** **447** **448** **449** **450** **451** **452** **453** **454** **455** **456** **457** **458** **459** **460** **461** **462** **463** **464** **465** **466** **467** **468** **469** **470** **471** **472** **473** **474** **475** **476** **477** **478** **479** **480** **481** **482** **483** **484** **485** **486** **487** **488** **489** **490** <



145
146
147
Figure 1: IR spectroscopy of compound 3a.
149



150
151
152
Figure 2: IR spectroscopy of compound 3b.

154 The *in vitro* cytotoxic activities of compounds (**3a**, **3b**) were evaluated. Minimum inhibitory concentrations of synthesized compound **3a** were found to be 50 µg/mL against MCF-7, HepG2 and PC3 lines; also, Minimum inhibitory concentrations of synthesized compound **3b** were found to be 50 µg/mL in all cell lines.

155 **Table (1):** Minimum inhibitory concentration of compound 3a against MCF-7 cell line.

159

Concentration (ug/ml)	MCF7-1
0.000	1.000
5.000	0.800

12.500	0.360
25.000	0.400
50.000	0.356

160

Table (2): Minimum inhibitory concentration of compound 3a against HepG2 cell line.

162

Concentration (ug/ml)	HEPG2 – 1
0.000	1.000
5.000	0.768
12.500	0.709
25.000	0.577
50.000	0.291

163

Table (3): Minimum inhibitory concentration of compound 3a against PC3 cell line.

165

Concentration (ug/ml)	PC3 – 1
0.000	1.000
5.000	0.922
12.500	0.711
25.000	0.702
50.000	0.565

166

Table (4): Minimum inhibitory concentration of compound 3b against MCF-7 cell line

167

Concentration (ug/ml)	MCF7-2
0.000	1.000
5.000	0.680
12.500	0.640
25.000	0.516
50.000	0.496

168

Table (5): Minimum inhibitory concentration of compound 3b against PC3 cell line

169

170

171

172

173

174

175

176

177

Concentration (ug/ml)	PC3 – 2
0.000	1.000
5.000	0.962
12.500	0.923
25.000	0.923
50.000	0.885

179

180

Table (6): Minimum inhibitory concentration of compound 3b against HepG2 cell line.

181

182

183

184
185
186
187
188
189

190

The apoptotic effect of compounds (3a, 3b), was evaluated through the estimation of caspase-3 and Bcl2 levels. The mean values of caspase-3 activity in positive control were found to be 2.6151 (ng/ml). Furthermore, the treatments with 3a and 3b showed a significant increase in caspase-3 activity 4.85 & 3.66 ± (ng/ml) (p<0.001); in comparison to the positive control group.

On the other hand, the mean values of Bcl-2 in positive control were found to be 3.7 (ng/mL). Furthermore, the treatments with 3a and 3b showed a significant decrease in Bcl-2 which found to be 2.97 & 2.92 (ng/mL) (p<0.001), in comparison to the positive control group.

198
199
200


Table (7): the effect of compounds (3a, 3b) effect on caspase-3 activity in all studied groups (mean ± SD):

Group	SD Mean ± SD (ng/ml)
Negative	4.8988± 0.14541
Positive	2.6151± 0.37377
Drug I	7.2785± 1.24961
Thr I	4.8452± 0.35076

Concentration (ug/ml)	HEPG2 – 2
0.000	1.000
5.000	0.573
12.500	0.455
25.000	0.417
50.000	0.364

Prev I	5.0785± 0.31448
Drug II	7.4477± 0.37329
Thr II	3.6605± 0.22552
Prev II	4.5075± 0.37144

201



202
203

Figure (1): the effect of compounds (3a, 3b) effect on caspase-3 activity in all studied groups


204

Table (8): The effect of compounds (3a, 3b) on Bcl2 activity in all studied groups (ng/mL):

205

Group	Mean \pm SD
Negative	2.4734 \pm 0.01002
Positive	3.7013 \pm 0.04840
Drug I	2.6513 \pm 128360
Thr I	2.9089 \pm 0.0717
Prev I	2.7310 \pm 0.15130
Drug II	3.0924 \pm 0.19262
Thr II	2.9171 \pm 0.08258
Prev II	2.7918 \pm 0.10419

206



207

Figure (2): The effect of compounds (3a, 3b) on Bcl2 activity in all studied groups.

208

209

4. DISCUSSION:

210

Cancer is a complex disease characterized by at least six hallmark characteristics. Some of these hallmarks, such as proliferation and resistance to cell death (including apoptosis) act at a cellular level and are frequently caused by changes in the genome. An increased rate of cellular proliferation is frequent, but not exclusively found in cancer cells [12]. Most cancer cells divide more often than normal cells and the process of cell division can be targeted to treat cancer patients. The aim of targeting cell proliferation is to arrest the cell cycle and/or cause cancer cell death using cytotoxic compounds (chemotherapy) or ionising radiation (radiation therapy). DNA is one of the main targets of these therapies because DNA replication is an essential phase of the cell cycle. Many of the cytotoxic agents commonly used to treat cancer patients cause high levels of DNA damage, that initiate cell cycle checkpoints, leading to cell cycle arrest and/or cell death [13].

221

The search for new chemo-preventive and anti-tumor agents that are more effective and less toxic has kindled great interest [14]. Medicinal organometallic complexes consist of platinum, ruthenium, iron, titanium, and gold among other metals. Fundamental studies have been carried out on the organometallic complexes in which the mechanism of action exert their medicinal effect (e.g., induce cell death in cancer cells), the synthesis of new organometallic compounds and the development of combination therapies containing organometallic components. Research has shown significant progress in utilization of transition metal complexes as anticancer agents [15].

229

Thiosemicarbazones have emerged as ligands of great biological activity. The ability of thiosemicarbazones to chelate metal ions has now been recognized as a major factor in their antiproliferative effects [16].

232

In the present study, we aimed to evaluate the anti-tumor properties of recently developed synthetic copper complexes of 2,3-dihydroxy benzaldehyde thiosami carbazone (3a,b), as anticancer agents, followed by evaluating for their in vitro anticancer properties against breast, liver and prostate cancer cell lines.

The *in vitro* cytotoxic activities of compounds (3a, 3b) were evaluated. Minimum inhibitory concentrations of synthesized compound 3a were found to be 50 µg/mL against MCF-7, HepG2 and PC3 cell lines; also, Minimum inhibitory concentrations of synthesized compound 3b were found to be 50 µg/mL in all cell lines, Compared to Koňariková *et al.*, who studied the cytotoxicity of new copper complex derivatives against MCF-7 breast cancer cell line, and found that they have antiproliferative activity against cancer cells but not against healthy cells as they have induced autophagy in the cancer cell line MCF-7 [17].

Copper-based complexes have been investigated on the assumption that endogenous metals may be less toxic to normal cells compared to cancer cells and can induce apoptotic cell death or autophagy. Apoptotic cell death and autophagy are programmed cell deaths without inflammation of the surrounding healthy tissue [18].

Also, other authors have reported that Schiff base Cu(II) complexes exhibit significant cytotoxic effects against several cancer cell lines, such as PC3 (human prostate cancer cell line) [19], MCF-7 (human breast carcinoma cells), apoptosis in human liver cancer cell line Hep-G2 cells [20].

The apoptotic effect of compounds 3a and 3b were evaluated by measurement Caspase-3 activity and Bcl-2 in the EAC cells.

The mean values of Caspase-3 activity in positive control were found to be 2.6151 (ng/mL). Furthermore, the treatments with 3a and 3b showed a significantly increase in Caspase-3 activity, 4.85 & 3.66 ± (ng/ml) respectively (p<0.001); compared to the positive control group. On the other hand, the mean values of Bcl-2 in positive control were found to be 2.9 & 2.9. Furthermore, the treatments with 3a and 3b showed a significantly decrease in Bcl-2, (ng/mL) respectively (p<0.001), compared to the positive control group. Our results are in concordance with previous studies which concluded the apoptotic effect of copper thiosemicarbazone complex derivatives [21].

5. CONCLUSION:

The compounds (3a & 3b) exhibited a significant anticancer activity towards MCF-7, HEPG2 and PC3 cancer cell lines. The synthesized compounds are good inducer for apoptosis.

6. REFERENCES:

[1]: Mohammed F.Z., EL-Deen I.M. and Tmamm A.S. (2019): Biochemical Studies on Coumarin Derivatives as Antioxidant and Antitumor Agents. Asian Journal of Research in Biochemistry AJRB. 9(2): 48917.

[2]: Tomasetti C., Li L., Vogelstein B. et al(2017):"Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention". Science. 355 (6331):1330–1334.

[3]: Alain F.(2017): Genetics, Epigenetics and Cancer; <i>Canc Therapy & Oncol Int J</i> ; 4(2):555-634.	274 275
[4]: Gasser G., Ott I. and Nils Metzler-Nolte.(2011): Organometallic Anticancer Compounds; <i>J. Med. Chem.</i> 54(3) 252–253.	276 277
[5]: Zaki M., Hairat S., and Aazam E.(2019): Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies; <i>RSC Adv</i> ;9, 3239-3278.	278 279 280
[6]: Thavasu W., Longhurst S., Joel P., Slevin L., Balkwill R.(1992): Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. <i>J Immunol Methods</i> .;30;153(1-2):115-124.	281 282 283
[7]: Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Jonathan T. Warren, Bokesch H., KenneyS., Boyd M.(1990): New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening <i>Journal of the National Cancer Institute</i> .; 82,(13) 4-8.	284 285 286
[8]: Vichai V and Kirtikara K., (2006): Sulforhodamine B colorimetric assay for cytotoxicity screening. <i>Nat Protoc</i> 1: 1112-1116.	287 288
[9]: Casciola-Rosen L., Nicholson D.W., Chong T., Rowan K.R., Thornberry N.A., Miller D.K., and Rosen A., (1996): Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. <i>J. Exp. Med</i> 183: 1957-1964.	289 290 291
[10]: Reed G., Poyner R., Larsen T., Wedekind J., Raymenta I.(1996): Structural and mechanistic studies of enolase, <i>Current Opinion in Structural Biology</i> .;6(6):736-743.	292 293
[11]: Levesque R., SPSS. (2007): Programming and Data Management: A Guide for SPSS and SAS Users, Fourth Edition, SPSS Inc., Chicago Ill.	294 295
[12]: Hanahan D. and Weinberg R. (2011): The hallmarks of cancer. <i>Cell</i> ;100(6):57–70.	296
[13]: Helleday T., Petermann E., Lundin C., Hodgson B., Sharma .A(2008): DNA repair pathways as targets for cancer therapy. <i>Nat Rev Cancer</i> .;8(3):193-204.	297 298 299
[14]: Anto R.J., Mukhopadhyay A., Denning K., Aggarwal B.B., (2002): Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage, and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. <i>Carcinogenesis</i> 23: 143–150.	300 301 302 303
[15]: Jakupec A., Galanski M., Arion V., Hartinger G., Keppler K.(2008): Antitumour metal compounds: More than theme and variations. <i>Dalton Transactions</i> .;2:183-194.	304 305
[16]: Arora S., Agarwal S., Singhal S.(2014): Anticancer Activities of Thiosemicarbazides/Thiosemicarbazones.; <i>Int J Pharm Pharm Sci</i> , 6, (9):34-41.	306 307
[17]: Koňariková K., Perdikaris G., Gbelcová H., Andrezálová L., Švéda M., Ruml T., Laubertová L., Režnáková S., Žitňanová I.(2016): Autophagy in MCF-7 cancer cells induced by copper complexes.; <i>Pharmacol Rep</i> .;68(6):1221-1224.	308 309 310
[18]: Liang C., Xia J., Lei D., Li X., Yao Q., Gao J.(2014): Synthesis, in vitro and in vivo antitumor activity of symmetrical bis-Schiff base derivatives of isatin. <i>Eur J Med Chem</i> .; 74(9):742-750.	311 312 313

[19]: Vyas A., Patitungkho S., Jamadar A., Adsule S., Padhyea S., Ahmad A.(2012): ATRA- 314
hydrazonate derivatives and their copper complexes against hormone-dependent (MCF-7), 315
hormoneindependent (MDA-MB-231and BT-20) breast cancer and androgen-independent (PC3) 316
prostate cancer cell lines. Inorg Chem Com.;23(11):17-20. 317

[20]: Francisco D., Peddi P., Hair J., Flood B., Cecil A., Kalogerinis P.(2009): Induction and 318
processing of complex DNA damage in human breast cancer cells MCF-7 and nonmalignant MCF- 319
10A cells. Free Rad Biol Med.;44(4):558-69. 320

[21]: Karlsson H., Fryknäs M., Strese S., Gullbo J., Larsson R., Sjöblom T., Pandzic T., Nygren P., 321
Westman G., Bremberg U.(2017): Mechanistic characterization of a copper containing 322
thiosemicarbazone with potent antitumor activity. Oncotarget., 8, 30217–3023410. 323

324
325
326
327
. 328
329

UNDER PEER REVIEW